Currently, intravenous infusions of human plasma-purified AAT preparations are used for the treatment of lung diseases associated with severe inherited AAT deficiency (circulating levels of AAT about 10% of normal). The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.